Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.
Malkin E, Zaric M, Kieh M, Baden LR, Fitz-Patrick D, Marini A, Yun H, Hayes P, Bromell R, Ayorinde M, Fernandez N, Varma R, Sigei F, Ward M, Pindolia H, Sewell S, Amini F, Blie J, Wilson B, Faley P, McCullough J, Tokpah F, Wisseh C, Towalid E, Hadawale S, Sayeed E, Hunt D, Keshavarzi N, Barin B, Maljkovic Berry I, Parks CL, Truter SG, Walker K, Vekemans J, Lehrman J, Engelbrecht M, Malherbe M, Laufer D, Philiponis V, Higgs E, Mutua G, Fast PE, Gupta SB; rVSVΔG-LASV-GPC Study Group.
Malkin E, et al.
N Engl J Med. 2025 Nov 6;393(18):1807-1818. doi: 10.1056/NEJMoa2501073.
N Engl J Med. 2025.
PMID: 41191941
Clinical Trial.